Publikationen von 0000-0002-9826-0753
(ORCID: 0000-0002-9826-0753)

Banales, Jesus M. , Marin, Jose J. G., Lamarca, Angela, Rodrigues, Pedro M. , Khan, Shahid A., Roberts, Lewis R. , Cardinale, Vincenzo, Carpino, Guido, Andersen, Jesper B., Braconi, Chiara, Calvisi, Diego F., Perugorria, Maria J., Fabris, Luca, Boulter, Luke, Macias, Rocio I. R., Gaudio, Eugenio, Alvaro, Domenico, Gradilone, Sergio A., Strazzabosco, Mario, Marzioni, Marco, Coulouarn, Cédric, Fouassier, Laura , Raggi, Chiara, Invernizzi, Pietro, Mertens, Joachim C., Moncsek, Anja, Rizvi, Sumera, Heimbach, Julie, Koerkamp, Bas Groot, Bruix, Jordi , Forner, Alejandro, Bridgewater, John, Valle, Juan W. und Gores, Gregory J. (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology 17 (9), S. 557-588. Volltext nicht vorhanden.

Bruix, Jordi , Tak, Won-Young , Gasbarrini, Antonio, Santoro, Armando, Colombo, Massimo, Lim, Ho-Yeong, Mazzaferro, Vincenzo , Wiest, Reiner, Reig, María , Wagner, Andrea und Bolondi, Luigi (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European Journal of Cancer 49 (16), S. 3412-3419. Volltext nicht vorhanden.